155 related articles for article (PubMed ID: 35467324)
1. Renal safety of tenofovir disoproxil fumarate and entecavir in liver transplant patients: a nationwide Korean registry study.
Lee J; Lee JG; Hwang S; Lee KW; Kim JM; Ryu JH; Kim BW; Choi DL; You YK; Kim DS; Nah YW; Kang KJ; Cho JY; Yu HC; Hong G; Choi D; Moon JI; Kim MS
Hepatol Int; 2022 Jun; 16(3):537-544. PubMed ID: 35467324
[TBL] [Abstract][Full Text] [Related]
2. Renal safety of tenofovir disoproxil fumarate and entecavir with hepatitis B immunoglobulin in liver transplant patients.
Lee J; Park JY; Yang SJ; Lee JY; Kim DG; Joo DJ; Kim MS; Kim SI; Lee JG
J Viral Hepat; 2020 Aug; 27(8):818-825. PubMed ID: 32302037
[TBL] [Abstract][Full Text] [Related]
3. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.
Kim SU; Seo YS; Lee HA; Kim MN; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
J Hepatol; 2019 Sep; 71(3):456-464. PubMed ID: 30959156
[TBL] [Abstract][Full Text] [Related]
4. Using the chronic kidney disease guidelines to evaluate the renal safety of tenofovir disoproxil fumarate in hepatitis B patients.
Tsai HJ; Chuang YW; Lee SW; Wu CY; Yeh HZ; Lee TY
Aliment Pharmacol Ther; 2018 Jun; 47(12):1673-1681. PubMed ID: 29696665
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the renal safety of tenofovir disoproxil fumarate in hepatitis B patients without chronic kidney disease.
Tsai HJ; Chuang YW; Yang SS; Chang YZ; Chang HR; Lee TY
J Viral Hepat; 2021 Nov; 28(11):1579-1586. PubMed ID: 34464999
[TBL] [Abstract][Full Text] [Related]
6. Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study.
Lampertico P; Berg T; Buti M; Pathil A; Petersen J; Ryder SD; Zoulim F; Botros I; Flaherty JF; Jump B; Op den Brouw ML; van Troostenburg A; Ramroth H;
Aliment Pharmacol Ther; 2020 Aug; 52(3):500-512. PubMed ID: 32583915
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir.
Viganò M; Loglio A; Labanca S; Zaltron S; Castelli F; Andreone P; Messina V; Ganga R; Coppola N; Marrone A; Russello M; Marzano A; Tucci A; Taliani G; Fasano M; Fagiuoli S; Villa E; Bronte F; Santantonio T; Brancaccio G; Occhipinti V; Facchetti F; Grossi G; Rumi M; Lampertico P
Liver Int; 2019 Mar; 39(3):484-493. PubMed ID: 30525275
[TBL] [Abstract][Full Text] [Related]
8. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial.
Lim YS; Gwak GY; Choi J; Lee YS; Byun KS; Kim YJ; Yoo BC; Kwon SY; Lee HC
J Hepatol; 2019 Jul; 71(1):35-44. PubMed ID: 30876946
[TBL] [Abstract][Full Text] [Related]
9. Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis.
Liu Z; Zhao Z; Ma X; Liu S; Xin Y
BMC Gastroenterol; 2023 Nov; 23(1):384. PubMed ID: 37950196
[TBL] [Abstract][Full Text] [Related]
10. Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B.
Jeong S; Shin HP; Kim HI
Intervirology; 2022; 65(2):94-103. PubMed ID: 34731856
[TBL] [Abstract][Full Text] [Related]
11. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
Papatheodoridis GV; Dalekos GN; Idilman R; Sypsa V; Van Boemmel F; Buti M; Calleja JL; Goulis J; Manolakopoulos S; Loglio A; Papatheodoridi M; Gatselis N; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Yurdaydin C; Esteban R; Janssen HLA; Berg T; Lampertico P
J Hepatol; 2020 Nov; 73(5):1037-1045. PubMed ID: 32553667
[TBL] [Abstract][Full Text] [Related]
12. Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection.
Choi J; Jo C; Lim YS
Hepatology; 2021 Feb; 73(2):661-673. PubMed ID: 32324905
[TBL] [Abstract][Full Text] [Related]
13. Risk of renal events during tenofovir disoproxil fumarate and entecavir antiviral prophylaxis in HBsAg-positive cancer patients undergoing chemotherapy.
Lee IC; Chao Y; Li CP; Su CW; Lan KH; Lin HC; Hou MC; Huang YH
J Viral Hepat; 2018 Dec; 25(12):1599-1607. PubMed ID: 30125436
[TBL] [Abstract][Full Text] [Related]
14. Risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis B patients receiving tenofovir disoproxil fumarate versus entecavir in the United States.
Kim WR; Telep LE; Jump B; Lu M; Ramroth H; Flaherty J; Gaggar A; Chokkalingam AP; Gordon SC
Aliment Pharmacol Ther; 2022 Apr; 55(7):828-835. PubMed ID: 35137422
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study.
Mak LY; Hoang J; Jun DW; Chen CH; Peng CY; Yeh ML; Kim SE; Huang DQ; Jeong JY; Yoon E; Oh H; Tsai PC; Huang CF; Ahn SB; Trinh H; Xie Q; Wong GLH; Enomoto M; Shim JJ; Lee DH; Liu L; Kozuka R; Cho YK; Jeong SW; Kim HS; Trinh L; Dao A; Huang R; Hui RW; Tsui V; Quek S; Khine HHTW; Ogawa E; Dai CY; Huang JF; Cheung R; Wu C; Chuang WL; Lim SG; Yu ML; Yuen MF; Nguyen MH
Hepatol Int; 2022 Feb; 16(1):48-58. PubMed ID: 34822056
[TBL] [Abstract][Full Text] [Related]
16. Tenofovir Versus Entecavir for the Treatment of Acute-on-Chronic Liver Failure due to Reactivation of Chronic Hepatitis B With Genotypes B and C.
Wan YM; Li YH; Xu ZY; Wu HM; Xu Y; Wu XN; Yang JH
J Clin Gastroenterol; 2019 Apr; 53(4):e171-e177. PubMed ID: 29659382
[TBL] [Abstract][Full Text] [Related]
17. Real-world single-center experience with entecavir and tenofovir disoproxil fumarate in treatment-naïve and experienced patients with chronic hepatitis B.
Kim YM; Shin HP; Lee JI; Joo KR; Cha JM; Jeon JW; Yoon JY; Kwak MS
Saudi J Gastroenterol; 2018; 24(6):326-335. PubMed ID: 30004042
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular carcinoma and death and transplantation in chronic hepatitis B treated with entecavir or tenofovir disoproxil fumarate.
Ha Y; Chon YE; Kim MN; Lee JH; Hwang SG
Sci Rep; 2020 Aug; 10(1):13537. PubMed ID: 32782369
[TBL] [Abstract][Full Text] [Related]
19. Long-term Nucleotide Analogue Treatment Has Higher Levels of Renal Toxicities than Does Entecavir in Patients with Chronic Hepatitis B.
Cho YY; Chang Y; Nam JY; Cho H; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
Gut Liver; 2020 Mar; 14(2):225-231. PubMed ID: 31060115
[TBL] [Abstract][Full Text] [Related]
20. Comparison of renal safety of tenofovir and entecavir in patients with chronic hepatitis B: Systematic review with meta-analysis.
Lee HY; Oh H; Park CH; Yeo YH; Nguyen MH; Jun DW
World J Gastroenterol; 2019 Jun; 25(23):2961-2972. PubMed ID: 31249453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]